Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Trial Profile

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Phase of Trial: Phase III

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Bortezomib (Primary) ; Thalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 01 Jun 2012 Results published in the European Journal of Haematology.
    • 08 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top